Loading...
•
Mar 31
Eton Q1 2025 Earnings Report
Eton posted record Q1 2025 revenue with strong product sales and licensing contributions.
Key Takeaways
Eton Pharmaceuticals delivered a standout Q1 2025, driven by 76% growth in product sales and newly added licensing revenue. Despite a net loss on a GAAP basis, the company posted positive non-GAAP earnings and expects continued growth from product launches and development milestones.
Total revenue rose to $17.3 million, up 117% year-over-year.
Product sales and royalties reached $14 million, up 76% YoY.
Non-GAAP EPS was $0.07 compared to $0.00 a year ago.
Cash position increased to $17.4 million with positive operating cash flow.
Eton
Eton
Eton Revenue by Segment
Revenue by Segment
Product Sales & Royalties Revenue
CapyFin.comLicensing Revenue
CapyFin.com Forward Guidance
Eton anticipates further growth in 2025 with additional product launches and regulatory milestones expected.
Positive Outlook
- ET-400 launch anticipated shortly after May 28 PDUFA date
- ET-600 NDA submitted with potential 2026 approval
- GALZIN and INCRELEX launches showing strong initial uptake
- Cash position improved to $17.4 million with positive cash flow
- Full-year revenue run rate expected to reach $80 million
Challenges Ahead
- Net loss of $1.6 million on a GAAP basis
- G&A expenses significantly elevated due to launch costs
- Continued reliance on milestone and licensing revenue for profit
- Severance and divestiture-related costs impacted profitability
- Inventory step-up expense reduced gross margins
Revenue & Expenses
Visualization of income flow from segment revenue to net income